Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc. Pine Brook, NJ 07058 USA, NDC 47781-355-03
Published July 14, 2021 · Recall initiated: February 26, 2021
Summary
FDA records drug Class II recall D-0649-2021, published July 14, 2021 and initiated February 26, 2021. Recalling firm: Alvogen, Inc; Status: Terminated; Reported quantity: 9,696 cartons; Lot: Lot #: 36924, Exp 6/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)
What to do
Voluntary: Firm initiated · Letter
Get an email if BUPRENORPHINE AND NALOXONE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BUPRENORPHINE AND NALOXONE
- Manufacturer
- Alvogen, Inc
- Distributor
- USA nationwide.
- UPC
- 0347781356118
- Lot
- Lot #: 36924, Exp 6/2021
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABuprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30-count bottles, Rx only, Distributed by: SunNovember 9, 2022
- FDAXylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Injection, USP), 1%, 300 mg/30 mL,July 14, 2021
- FDATopotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals USA, Inc. North Whales, PAJuly 14, 2021
- FDAContinuous CT Fluoroscopy DVI Ceiling Mount CCT Arm DVI Option - Monitor 882446 - Vereos PET/CTJuly 7, 2021
- FDAContinuous CT Fluoroscopy DVI Ceiling Mount CCT Arm DVI Option - Monitor 728332 - IQon Spectral CT : IQonJuly 7, 2021
- FDAContinuous CT Fluoroscopy DVI Ceiling Mount CCT Arm DVI Option - Monitor Bracket Assembly for use with CT andJuly 7, 2021
Questions about this recall
Was Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc. Pine Brook, NJ 07058 USA, NDC 47781-355-03 recalled?
Yes. FDA published recall D-0649-2021 on July 14, 2021. Reported hazard: Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BUPRENORPHINE AND NALOXONE. UPC: 0347781356118.